{"links":{"html":"https://www.erudio.com/reports/apex-breast01-nct06561607","json":"https://www.erudio.com/reports/apex-breast01-nct06561607.json","markdown":"https://www.erudio.com/reports/apex-breast01-nct06561607.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"apex-breast01-06561607"}},"request":"https://www.erudio.com/contact?report=apex-breast01-06561607"},"offer":{"cited_commentary_sources":12,"verified_hcp_statements":39,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"apex-breast01-nct06561607"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=apex-breast01-06561607","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/apex-breast01-nct06561607","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T08:46:49.650921Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)"},{"claim_count":8,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":9,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":8,"coverage":"discussed","id":"A1","source_count":5,"title":"APEX-Breast01: biparatopic differentiation and perceived ADC similarity"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":1,"title":"APEX-Breast01 and HORIZON-Breast06: limits of numerical ranking"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":7,"title":"TQB2102 placement relative to T-DXd and internationally available alternatives"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"TQB2102 application acceptance versus marketing approval"}],"counts":{"cited_sources":13,"claims_by_expression_type":{"comparison":6,"interpretation":11,"opinion":3,"primary_context":2,"question":4,"restatement":5,"uncertainty":3,"unspecified":5},"claims_by_kind":{"protocol_statement":2,"source_observation":37},"clinician_statements":7,"evidence_units":24,"findings":6,"organisational_accounts":2,"people_cited":11,"people_identity_verified":9,"people_total":11,"screened_sources":18,"verified_claims":39},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":4,"experience":0,"questions":1,"restated":0,"views":3},"has_counterview":true,"limitations":2,"links":{"context":2,"support":10},"ma_question":true,"named_voices":6,"passages":11,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"The unresolved comparator question is T-DXd, not chemotherapy alone"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":3,"views":3},"has_counterview":true,"limitations":3,"links":{"context":2,"support":10},"ma_question":true,"named_voices":5,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Manageability language coexists with higher severe toxicity and unresolved long-term safety"},{"id":"F3","structure":{"claims":17,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":6,"views":7},"has_counterview":true,"limitations":3,"links":{"context":4,"support":18},"ma_question":true,"named_voices":9,"passages":15,"sources":10,"sources_by_kind":{"commentary":9,"media":1}},"title":"Strong efficacy enthusiasm does not establish an overall-survival benefit"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":4,"views":3},"has_counterview":true,"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":5,"passages":9,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"The biparatopic design has a rationale, but its added clinical contribution remains unproven"},{"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":5,"support":7},"ma_question":true,"named_voices":0,"passages":5,"sources":1,"sources_by_kind":{"media":1}},"title":"Matching PFS medians and nearby hazard ratios do not support an ADC ranking"},{"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":3},"has_counterview":true,"limitations":2,"links":{"context":1,"support":5},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Practical placement remains conditional on available alternatives, benefit–risk and regulatory status"}],"medical_affairs_question":"What added efficacy–safety value over T-DXd or another locally available ADC would justify TQB2102’s place in the treatment pathway?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Chemotherapy superiority does not settle the T-DXd question"},{"id":"section-2","level":2,"title":"Manageability language must travel with severe-toxicity and ILD qualifications"},{"id":"section-3","level":2,"title":"Enthusiasm is strong; survival remains unproven"},{"id":"section-4","level":2,"title":"Biparatopic differentiation remains an unproven contribution"},{"id":"section-5","level":2,"title":"Identical medians are not a head-to-head comparison"},{"id":"section-6","level":2,"title":"Availability and regulatory status keep placement conditional"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":5}],"id":"T1","label":"Primary endpoint: Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":8}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":5},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":8},{"id":"F3","shared_claims":6},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T08:46:49.650921Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T14:59:35Z","record_hash":"6be7f341e150311bf98cb98de2267aaa9a00e1a1ae4324ce056bbf61f4ab0677","release_hash":"6c50ca10cfb120f45b0a1b7a73964fee9a145c954f9e0f727148e27772a78521","report_id":"erudio-nct06561607","run_id":"1fe55469-ec8a-42f4-949a-eb2df016f3d0","schema_version":"5.0","slug":"apex-breast01-06561607","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"APEX-Breast01 asks whether TQB2102 delays cancer progression compared with chemotherapy in HR-positive, HER2-low advanced breast cancer without prior chemotherapy for advanced disease. An X poster leaves TQB2102’s place among available ADCs unsettled. That poster welcomes efficacy, while treatment toxicity draws scrutiny in another X post. In the YouTube discussion, whether TQB2102 extends survival and adds clinical value over existing ADCs remains an open question.","meta_description":"18 sources screened · 39 verified statements (7 from clinicians verified by NPI or staff page) from 13 sources · 6 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-f5504546fe9757127184","claim-58cde8d056f42fe2d002"],"id":"F1","paraphrase":"X posts raise questions about head-to-head ADC studies and comparisons of efficacy and safety between TQB2102 and T-DXd.","publication_caveats":["The posters’ clinical roles are not confirmed in the sources reviewed for this edition.","Not every part of these threads was examined, so additional views or qualifications may be missing."],"source_channel":"x_thread","source_date":"2026-10-23","title":"The unresolved comparator question is T-DXd, not chemotherapy alone"},{"cited_claim_ids":["claim-2fb80c394c759bed1241","claim-1e26807804bce2b63688"],"id":"F5","paraphrase":"A YouTube discussion asks how progression-free survival results can be compared between TQB2102 and SHR-A1811.","publication_caveats":["The speaker is not identified, and their clinical role is not stated in the sources reviewed for this edition.","Not every part of the video was examined, so additional views or qualifications may be missing."],"source_channel":"youtube","source_date":"2026-10-26","title":"Matching PFS medians and nearby hazard ratios do not support an ADC ranking"}]},"publication":{"approved_at":"2026-10-29T14:59:35Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":18},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on chemotherapy-naive patient selection, progression-free survival and interstitial lung disease with the trial intervention versus chemotherapy.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","18 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are a limited collection of posts and a video, not a representative sample of HCP opinion. Reposts and repeated quotations should not be counted as independent endorsements.","Parts of several sources were not fully assessed. Discussion using alternative wording, transcription variants or no trial name may be missing, so the report cannot establish that all relevant views or qualifications have been captured.","The video’s explanation of activity below the conventional HER2-positive threshold concerns possible therapeutic effects of certain ADCs, not guaranteed activity. Its diagnostic-selection rationale should not be read as an additional APEX-Breast01 efficacy result.","No full protocol or exact-trial results publication was available. The registry material describes planned methods and has no posted results; efficacy and safety figures in this report remain attributed accounts from commentary.","No exact regulatory label matching the registry’s named interventions was available. The reported Chinese application acceptance does not independently establish marketing approval, access or reimbursement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The registry’s planned enrollment of 542 and commentary reports of 543 participants are not reconciled here. Differences in reported response populations and safety summaries should likewise not be combined into a single independently verified dataset.","Cross-trial comparisons cannot establish that a control arm was weak, that similar medians imply equivalent efficacy, or that one ADC is safer. The report preserves those interpretations and cautions as expressed rather than adjudicating them."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":11,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":12,"methods":1},"count":13,"evidence_window":{"end":"2026-10-26","start":"2026-10-23"},"retrieval_snapshot":"2026-10-29T07:57:35.601846Z","timeline":[{"count":11,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06561607:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06561607:context","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113573098209648659:3edb4c78-5983-4a5f-82bb-bc82db97013f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113601562711056763:a08b0eeb-9d34-4e2c-b450-c628be7ccd5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113602178724086042:2a9a6138-d636-481f-95e0-7ab35dea6065","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113602182259904985:08165595-48ff-4426-92a1-c7da0141d2e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113602220944134484:476df652-6b4a-4bde-b414-345332916d53","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113602268939665437:48d062a3-66c2-4bd0-bf96-4b2a525352bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113602537396023795:f80f04fe-fc63-4548-8cae-d8fac11bc86c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113602959313653788:a9985eee-fd6a-4d39-9956-bec8751507c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113603316718416015:9cf568c5-ae20-4b45-824a-b2f9fb630cef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113603358787305624:bafeaebf-1c5f-4030-bf32-6520da124b58","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113603452353798538:b2b46af2-a4cb-4123-89d7-77b05807fc4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113603917506617410:f05df498-3ae1-425e-8416-68585485815d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113607208344727916:ab511761-b314-49fc-ba46-e64bda8e3b23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113650531323216088:562e3d40-5851-4171-8240-11809cc9afb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113684923236102279:69bca788-3a3f-4fab-9598-27fba3aee3aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113917771159327224:77c6f6e8-0971-46c8-bcdd-f314eab10e42","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:51rLCK45EWY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:zkkLeK-efVM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":18},"count":18,"evidence_window":{"end":"2026-10-26","start":"2026-10-23"},"retrieval_snapshot":"2026-10-29T07:57:35.611545Z","timeline":[{"count":17,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: tqb2102 for injection","status":"unmapped"},{"reason":"Unmapped registry intervention: chemotherapy drug (capecitabine/paclitaxel/albumin paclitaxel)","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"APEX-Breast01","aliases":["APEX-Breast01","TQB2102-III-01","A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer"],"brief_title":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Breast Cancer"],"enrollment":{"count":542,"type":"ESTIMATED"},"interventions":[{"name":"TQB2102 for Injection","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06561607","official_title":"A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","other_names":[{"kind":"also","name":"APEX-B01"}],"overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Designed to demonstrate that in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer, TQB2102 for injection significantly prolongs progression-free survival in subjects compared to investigator-selected chemotherapy.","measure":"Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)","timeFrame":"Up to 25 months"}],"registered_date":{"date":"2024-08-20","type":"ACTUAL"},"registry_last_updated":"2026-09-10","registry_url":"https://clinicaltrials.gov/study/NCT06561607","short_name":"APEX-Breast01","short_name_basis":"canonical_name","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","start_date":{"date":"2024-10-11","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"TQB2102-III-01","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}